These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Immunogenicity of Antigen Adjuvanted with AS04 and Its Deposition in the Upper Respiratory Tract after Intranasal Administration. Xu H; Alzhrani RF; Warnken ZN; Thakkar SG; Zeng M; Smyth HDC; Williams RO; Cui Z Mol Pharm; 2020 Sep; 17(9):3259-3269. PubMed ID: 32787271 [TBL] [Abstract][Full Text] [Related]
7. Effect of sublingual administration with a native or denatured protein allergen and adjuvant CpG oligodeoxynucleotides or cholera toxin on systemic T(H)2 immune responses and mucosal immunity in mice. Huang CF; Wang CC; Wu TC; Chu CH; Peng HJ Ann Allergy Asthma Immunol; 2007 Nov; 99(5):443-52. PubMed ID: 18051215 [TBL] [Abstract][Full Text] [Related]
8. Intranasal immunization with phosphorylcholine induces antigen specific mucosal and systemic immune responses in mice. Tanaka N; Fukuyama S; Fukuiwa T; Kawabata M; Sagara Y; Ito HO; Miwa Y; Nagatake T; Kiyono H; Kurono Y Vaccine; 2007 Mar; 25(14):2680-7. PubMed ID: 17270319 [TBL] [Abstract][Full Text] [Related]
9. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit. Boyaka PN; Ohmura M; Fujihashi K; Koga T; Yamamoto M; Kweon MN; Takeda Y; Jackson RJ; Kiyono H; Yuki Y; McGhee JR J Immunol; 2003 Jan; 170(1):454-62. PubMed ID: 12496431 [TBL] [Abstract][Full Text] [Related]
10. Cytokine responses to recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant. Maeyama J; Isaka M; Yasuda Y; Matano K; Kozuka S; Taniguchi T; Ohkuma K; Tochikubo K; Goto N Microbiol Immunol; 2001; 45(2):111-7. PubMed ID: 11293476 [TBL] [Abstract][Full Text] [Related]
11. The identification of plant lectins with mucosal adjuvant activity. Lavelle EC; Grant G; Pusztai A; Pfüller U; O'Hagan DT Immunology; 2001 Jan; 102(1):77-86. PubMed ID: 11168640 [TBL] [Abstract][Full Text] [Related]
12. Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy. Wiedermann U; Jahn-Schmid B; Lindblad M; Rask C; Holmgren J; Kraft D; Ebner C Int Immunol; 1999 Jul; 11(7):1131-8. PubMed ID: 10383946 [TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb. Martin M; Metzger DJ; Michalek SM; Connell TD; Russell MW Infect Immun; 2000 Jan; 68(1):281-7. PubMed ID: 10603399 [TBL] [Abstract][Full Text] [Related]
14. Nasally administered cholera toxin A-subunit acts as a mucosal adjuvant. Campos EA; Namikoshi J; Maeba S; Yamamoto M; Fukumoto M; Yamamoto H J Oral Sci; 2003 Mar; 45(1):25-31. PubMed ID: 12816361 [TBL] [Abstract][Full Text] [Related]
15. Zonula occludens toxin is a powerful mucosal adjuvant for intranasally delivered antigens. Marinaro M; Di Tommaso A; Uzzau S; Fasano A; De Magistris MT Infect Immun; 1999 Mar; 67(3):1287-91. PubMed ID: 10024572 [TBL] [Abstract][Full Text] [Related]
16. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. Roberts M; Bacon A; Rappuoli R; Pizza M; Cropley I; Douce G; Dougan G; Marinaro M; McGhee J; Chatfield S Infect Immun; 1995 Jun; 63(6):2100-8. PubMed ID: 7768587 [TBL] [Abstract][Full Text] [Related]
17. Mucosal adjuvant properties of the Shigella invasin complex. Kaminski RW; Turbyfill KR; Oaks EV Infect Immun; 2006 May; 74(5):2856-66. PubMed ID: 16622224 [TBL] [Abstract][Full Text] [Related]
18. Effect of neonatal sublingual vaccination with native or denatured ovalbumin and adjuvant CpG or cholera toxin on systemic and mucosal immunity in mice. Huang CF; Wu TC; Chu YH; Hwang KS; Wang CC; Peng HJ Scand J Immunol; 2008 Nov; 68(5):502-10. PubMed ID: 18822109 [TBL] [Abstract][Full Text] [Related]
19. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. Marinaro M; Staats HF; Hiroi T; Jackson RJ; Coste M; Boyaka PN; Okahashi N; Yamamoto M; Kiyono H; Bluethmann H; Fujihashi K; McGhee JR J Immunol; 1995 Nov; 155(10):4621-9. PubMed ID: 7594461 [TBL] [Abstract][Full Text] [Related]
20. Mucosal immunity of nasopharynx: an experimental study in TCR-transgenic (OVA23-3) mice. Yamada T; Kataoka S; Ogasawara K; Ishimitsu R; Hashigucci K; Suzuki T; Kawauchi H Rhinology; 2005 Sep; 43(3):190-8. PubMed ID: 16218512 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]